Science
Mechanism of Action
This corticosteroid exerts its effects by binding to intracellular glucocorticoid receptors, which then translocate to the cell nucleus to modulate gene expression. This process leads to the inhibition of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α, and suppresses inflammatory mediators like prostaglandins by inhibiting phospholipase A2. It also reduces leukocyte migration and diminishes the function of immune cells, including macrophages and T-lymphocytes, thereby mitigating inflammation and immune responses. Minor mineralocorticoid effects are also observed.
Research
Clinical Evidence
High confidenceN/A
Key findings
- 01 In pharmaceutical contexts, oral solutions of hydrocortisone succinate demonstrated chemical stability at a concentration of 1 mg/mL across a pH range of 5.5 to 7.4 for at least 14 days when stored under refrigeration.
- 02 Intravenous or intramuscular dosages for severe medical conditions typically range from 100 mg to 500 mg or more, administered every 2, 4, or 6 hours depending on severity, with 50 mg every 6 hours cited for conditions like septic shock.
Transparency
Dusting Analysis
Hydroxycortisone succinate is a potent pharmaceutical corticosteroid. Its potential for systemic absorption through the skin in amounts capable of causing harm, including severe systemic side effects, renders it unsuitable for cosmetic dusting applications. Its use is strictly regulated to prescription pharmaceutical formulations.
The Formula
Formulation
Stability
Optimal chemical stability for hydrocortisone succinate oral solutions is observed at pH 5.5 to 7.4 when stored under refrigeration (3–7°C) for a minimum of 14 days. It degrades rapidly under other storage conditions and is sensitive to heat, precluding autoclaving. Reconstituted injection solutions typically exhibit a pH range of 7 to 8.
Conflicts
- Physical incompatibilities have been noted when combining 1mg/mL hydrocortisone sodium succinate with 2mg/mL midazolam or 2mg/mL ciprofloxacin, resulting in a significant reduction in hydrocortisone concentration.
- It is generally advised against diluting or mixing with other solutions unless specifically indicated due to possible physical incompatibilities.
- Diluents containing benzyl alcohol must not be used for intrathecal administration.
Safety
Safety Profile
As an FDA-approved drug, hydrocortisone sodium succinate is primarily intended for injectable or oral pharmaceutical use. It can be absorbed percutaneously in medically significant quantities, potentially leading to adverse effects such as slight irritation, skin thinning, impaired wound healing, and, with long-term systemic exposure, serious conditions like Cushing's syndrome or increased infection risk. It lacks specific cosmetic safety review status (CIR/SCCS).
Your Skin
Skin Compatibility
Our Assessment
Verdict
Given its status as a potent pharmaceutical drug with significant potential for systemic absorption and severe side effects, hydroxycortisone succinate is not suitable for cosmetic formulations and should be avoided in such applications.
Related
Similar Ingredients
Finding similar ingredients…